Recent studies have found that the previous method of predicting drug sensitivity based on exon location classification is unscientific and that classification based on structural changes in EGFR mutations can more effectively guide the treatment of EGFR-mutated NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.